Life sciences and the R&D tax credit UK: experimental development, not routine compliance

Many life sciences teams still ask what actually qualifies for the R&D tax credit UK. The short answer is that HMRC looks for experimental development that resolves real technological uncertainties. Routine regulatory paperwork does not qualify, but the experiments and engineering that unlock clinical and manufacturing progress often do. 

What does the R&D tax credit UK cover in life sciences? 

It covers work that seeks to resolve scientific or technological uncertainties through a systematic programme of testing and iteration. In practice, that means planned experiments and engineering designed to achieve outcomes that competent professionals could not guarantee at the outset. 

What counts as experimental development in life sciences? 

Examples that typically qualify when uncertainty is genuine and the work is systematic: 

• Assay development and validation where sensitivity, specificity or robustness must be proven beyond known methods. 

• Formulation R&D to achieve stability, bioavailability or delivery characteristics not available off the shelf. 

• CMC and bioprocess optimisation to achieve yield, purity or consistency at scale. 

• Device engineering and firmware where performance targets require new designs, architectures or control algorithms. 

• Diagnostics and biomarker development where analytical performance must be demonstrated across challenging sample types. 

• Manufacturing scale up trials that solve process reliability or quality problems under real conditions. 

What does not usually qualify because it is routine compliance? 

Activities that implement known techniques without overcoming technological uncertainty are unlikely to qualify for UK R&D tax credit. Use this table to separate the two. 

Where do clinical and regulatory steps fit? 

Clinical and regulatory activity can include qualifying R&D when technical uncertainties are being resolved. The paperwork itself does not qualify. The underlying experiments and engineering that deliver evidence can qualify if they push beyond the known baseline. 

Examples: 

• Protocol-driven clinical method changes to overcome measurement or device performance limits. 

• Analytical method development for sample handling or detection that is not available as a standard method. 

• Design modifications prompted by safety or usability findings that require new engineering and validation. 

• Process changes to meet GMP at scale where the solution was not known at the start. 

Which cost lines are commonly eligible in life sciences? 

Eligibility always depends on the facts, but the following often feature in strong claims: 

• Staff time for scientists, engineers, data specialists and technicians who carry out qualifying experiments and engineering. 

• Consumables and materials consumed by R&D, including reagents, prototype parts and test articles. 

• Clinical and lab costs that are integral to qualifying experiments, where they form part of resolving uncertainty. 

• Software and data costs directly used for experiments, modelling or analysis. 

• Subcontracted R&D where external specialists perform qualifying tasks. Treatment can vary by period and contract terms, so document scope precisely. 

• Prototype tooling and test rigs where consumed or materially transformed during the R&D. 

Care is needed with grants, overseas activity and contracted out work. Allocate costs clearly and keep a one page treatment note for each project to avoid double counting. 

Evidence that convinces HMRC 

HMRC expects a clear technical story and traceable numbers. The best files contain: 

• Protocol and experiment logs with objectives, parameters, results and deviations. 

• Negative results that show why the outcome was not obvious at the start. 

• Benchmarking and baselines against current methods or literature. 

• Design history and change records for devices and processes. 

• Quality and risk registers that capture failure modes and mitigations. 

• Named time records reconciled to payroll and work packages. 

• Supplier statements of work that describe the qualifying contribution, not just “services”. 

If you mention it, reference it. If you cannot reference it, either generate the evidence or remove the claim. 

Common pitfalls that trigger questions 

• Narratives written in marketing language rather than technical language. 

• Mixing routine compliance activity with qualifying experiments in the same work package. 

• Time sheets that do not reconcile to payroll for named staff. 

• Subcontractor invoices that fail to describe the R&D activity performed. 

• Overseas and grant interactions left undocumented, leading to allocation errors. 

• Copy and paste submissions that repeat the same wording across projects or years. 

CFO checklist for an enquiry ready life sciences claim 

• Period correct mapping: confirm which rules apply to each accounting period and project. 

• Four part narrative: baseline knowledge, technological uncertainties, systematic work, results. 

• Cost traceability: link staff time and supplier costs to specific experiments and designs, then to the CT600. 

• Evidence index: protocols, test data, photos, design history, change logs, references. 

• Governance: sign offs, version control and a short note on subcontractor, grant and overseas treatment. 

• 24 hour enquiry pack: assemble the above before filing so responses are fast and consistent. 

Expert view 

“Smaller life sciences companies and research consortia rely on larger players for partnerships and additional investment. In this environment, getting the R&D tax credit UK right matters for runway and momentum. The strongest claims are built on systematic experiments, clear baselines and honest write ups of failure as well as success,” says Dr Fawzi Abou-Chahine, Funding Director – FI Group UK 

Why process quality matters 

Enquiry activity across the market has been elevated. Independent commentary points to higher levels of challenge than in the past. Against that backdrop, FI Group reports that only 3 per cent of its client claims entered enquiry in the last cycle, compared with an industry picture of around 18 per cent. The firm attributes the outcome to evidence first drafting, pre submission quality assurance and assembling an enquiry pack before filing. 

The takeaway for life sciences teams 

Focus on experimental development that resolves genuine uncertainties. Capture protocols, failures and design changes as you go. Reconcile costs to the people and suppliers who did the work. Keep grant and subcontractor treatment notes simple and precise. Do this consistently and the R&D tax credit UK becomes a reliable part of the funding mix rather than a yearly scramble.